Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review

@article{Vathiotis2021TinzaparinSI,
  title={Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review},
  author={I. Vathiotis and N. Syrigos and E. Dimakakos},
  journal={Clinical and Applied Thrombosis/Hemostasis},
  year={2021},
  volume={27}
}
Low-molecular-weight heparins are approved for primary and secondary venous thromboembolism prevention. Tinzaparin is the low-molecular-weight heparin with the highest average molecular weight. The purpose of this systematic review is to provide an update regarding the safety profile of tinzaparin, prescribed either as a prophylactic or as a therapeutic regimen for venous thromboembolism in special populations, including cancer patients and patients with renal impairment. We identified… Expand
1 Citations

Figures and Tables from this paper

References

SHOWING 1-10 OF 34 REFERENCES
The Role of Tinzaparin in Oncology
  • E. Dimakakos, I. Vathiotis, K. Syrigos
  • Medicine
  • Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
  • 2018
Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
Treatment of venous thromboembolism with tinzaparin in oncological patients.
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
...
1
2
3
4
...